Paper22856463
Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.
Xuan L and 9 others. J Hematol Oncol, 2012. Cited by 75 papers, by iCite.
Cite this record
ConductScience Library. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. Papers, record 22856463. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22856463
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.
- PubMed
Topics26
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cytomegalovirus Infections | Major topic |
| Epstein-Barr Virus Infections | Major topic |
| Hematologic Neoplasms | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Transplantation Conditioning | Major topic |
| Adolescent | |
| Adult | |
| Child | |
| Cytomegalovirus | |
| DNA, Viral | |
| Female | |
| Flow Cytometry | |
| Graft vs Host Disease | |
| Herpesvirus 4, Human | |
| Humans | |
| Male | |
| Middle Aged | |
| Prognosis | |
| Prospective Studies | |
| RNA, Messenger | |
| Real-Time Polymerase Chain Reaction | |
| Risk Factors | |
| Survival Rate | |
| Transplantation, Homologous | |
| Viremia | |
| Young Adult |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20970670 | Reactivations of cytomegalovirus, human herpes virus 6, and Epstein-Barr virus differ with respect to risk factors and clinical outcome after hematopoietic stem cell transplantation. | Transplant Proc | 2010 | https://conductscience.org/library/papers/20970670 | PubMed |
| 2 | 19264919 | Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. | Blood | 2009 | https://conductscience.org/library/papers/19264919 | PubMed |
| 3 | 21997849 | Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus. | Ann Hematol | 2012 | https://conductscience.org/library/papers/21997849 | PubMed |
| 4 | 20482561 | Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients. | Clin Transplant | 2011 | https://conductscience.org/library/papers/20482561 | PubMed |
| 5 | 11801465 | Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. | Haematologica | 2002 | https://conductscience.org/library/papers/11801465 | PubMed |
| 6 | 11157478 | Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. | Blood | 2001 | https://conductscience.org/library/papers/11157478 | PubMed |
| 7 | 17448963 | Risk assessment in haematopoietic stem cell transplantation: conditioning. | Best Pract Res Clin Haematol | 2007 | https://conductscience.org/library/papers/17448963 | PubMed |
| 8 | 19497070 | Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. | Transpl Infect Dis | 2009 | https://conductscience.org/library/papers/19497070 | PubMed |
| 9 | 17921853 | Human herpesvirus 6 (HHV-6)-associated pleurisy after unrelated cord blood transplantation in children with chemotherapy-resistant malignant Lymphoma. | J Pediatr Hematol Oncol | 2007 | https://conductscience.org/library/papers/17921853 | PubMed |
| 10 | 22424172 | Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. | J Hematol Oncol | 2012 | https://conductscience.org/library/papers/22424172 | PubMed |
| 11 | 14576063 | Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. | Blood | 2004 | https://conductscience.org/library/papers/14576063 | PubMed |
| 12 | 11877269 | Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. | Blood | 2002 | https://conductscience.org/library/papers/11877269 | PubMed |
| 13 | 19043458 | Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. | Bone Marrow Transplant | 2009 | https://conductscience.org/library/papers/19043458 | PubMed |
| 14 | 8652385 | A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). | Br J Haematol | 1996 | https://conductscience.org/library/papers/8652385 | PubMed |
| 15 | 21323694 | The impact of early viral infections and graft-versus-host disease on immune reconstitution following paediatric stem cell transplantation. | Scand J Immunol | 2011 | https://conductscience.org/library/papers/21323694 | PubMed |
| 16 | 16151426 | Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. | Bone Marrow Transplant | 2005 | https://conductscience.org/library/papers/16151426 | PubMed |
| 17 | 15090449 | Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. | Blood | 2004 | https://conductscience.org/library/papers/15090449 | PubMed |
| 18 | 22856463 | Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. | J Hematol Oncol | 2012 | https://conductscience.org/library/papers/22856463 | PubMed |
| 19 | 12171713 | Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. | Cytotherapy | 2001 | https://conductscience.org/library/papers/12171713 | PubMed |
| 20 | 18300756 | Novel strategies for relapsed and refractory acute myeloid leukemia. | Curr Opin Hematol | 2008 | https://conductscience.org/library/papers/18300756 | PubMed |
Cited by53
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 75 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42237268 | Impact of RUNX1 mutations at distinct sites on the clinical characteristics and prognosis of patients with acute myeloid leukemia. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42237268 | PubMed |
| 42056205 | Letermovir prophylaxis and early CMV DNAemia after allogeneic hematopoietic stem cell transplantation: a real‑world study from China. | Sci Rep | 2026 | https://conductscience.org/library/papers/42056205 | PubMed |
| 41550532 | Efficacy and safety of Busulfan-Fludarabine versus Busulfan-Cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplant in hematologic malignancy patients: a meta-analysis of randomized controlled trials and observational studies. | Ther Adv Hematol | 2026 | https://conductscience.org/library/papers/41550532 | PubMed |
| 41122689 | Increased EBV infection and relapse following haploidentical hematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis: a propensity score matching analysis. | Front Cell Infect Microbiol | 2025 | https://conductscience.org/library/papers/41122689 | PubMed |
| 39746694 | [Maribavir treatment for refractory and drug-intolerant cytomegalovirus viremia and disease after allogeneic hematopoietic stem cell transplantation: a clinical analysis of 25 cases]. | Zhonghua Xue Ye Xue Za Zhi | 2024 | https://conductscience.org/library/papers/39746694 | PubMed |
| 39746692 | [Early cellular immune exhaustion in patients with Epstein-Barr virus activation following haploidentical hematopoietic stem cell transplantation]. | Zhonghua Xue Ye Xue Za Zhi | 2024 | https://conductscience.org/library/papers/39746692 | PubMed |
| 39398542 | CD34+ cell dose and CMV viremia after haploidentical hematopoietic stem cell transplantation: a retrospective study. | Am J Transl Res | 2024 | https://conductscience.org/library/papers/39398542 | PubMed |
| 39390260 | Epstein-Barr virus as a potentiator of autoimmune diseases. | Nat Rev Rheumatol | 2024 | https://conductscience.org/library/papers/39390260 | PubMed |
| 39360328 | Cytomegalovirus results in poor graft function via bone marrow-derived endothelial progenitor cells. | Front Microbiol | 2024 | https://conductscience.org/library/papers/39360328 | PubMed |
| 39077735 | The impact of the donors' COVID-19 status on the outcomes of allogeneic hematopoietic stem cell transplantation: a multi-center retrospective study. | Front Microbiol | 2024 | https://conductscience.org/library/papers/39077735 | PubMed |
| 38856035 | T-Cell Posttransplant Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: Case Series and Systemic Review. | Cell Transplant | 2024 | https://conductscience.org/library/papers/38856035 | PubMed |
| 38680718 | Rate, Risk Factors, and Outcomes of Invasive Fungal Infections in Patients with Hematologic Malignancies. | Int J Hematol Oncol Stem Cell Res | 2024 | https://conductscience.org/library/papers/38680718 | PubMed |
| 37875840 | Influence on therapeutic outcome of platelet count at diagnosis in patients with de novo non-APL acute myeloid leukemia. | BMC Cancer | 2023 | https://conductscience.org/library/papers/37875840 | PubMed |
| 37474631 | Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study. | Ann Hematol | 2023 | https://conductscience.org/library/papers/37474631 | PubMed |
| 36742189 | Machine learning algorithm as a prognostic tool for Epstein-Barr virus reactivation after haploidentical hematopoietic stem cell transplantation. | Blood Sci | 2023 | https://conductscience.org/library/papers/36742189 | PubMed |
| 36709164 | [Chinese consensus on the diagnosis and management of Epstein-Barr virus-related post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation (2022)]. | Zhonghua Xue Ye Xue Za Zhi | 2022 | https://conductscience.org/library/papers/36709164 | PubMed |
| 36709144 | [The Chinese consensus on the management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation patients (2022)]. | Zhonghua Xue Ye Xue Za Zhi | 2022 | https://conductscience.org/library/papers/36709144 | PubMed |
| 36171605 | Cytomegalovirus infection may be oncoprotective against neoplasms of B-lymphocyte lineage: single-institution experience and survey of global evidence. | Virol J | 2022 | https://conductscience.org/library/papers/36171605 | PubMed |
| 36050712 | Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial. | BMC Med | 2022 | https://conductscience.org/library/papers/36050712 | PubMed |
| 35615363 | The Incidence, Outcomes, and Risk Factors of Secondary Poor Graft Function in Haploidentical Hematopoietic Stem Cell Transplantation for Acquired Aplastic Anemia. | Front Immunol | 2022 | https://conductscience.org/library/papers/35615363 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| FCGR3A | 2214 | PubTator's text mining | https://conductscience.org/library/genes/2214 | NCBI Gene |
| HLA-A | 3105 | PubTator's text mining | https://conductscience.org/library/genes/3105 | NCBI Gene |
| ISG20 | 3669 | PubTator's text mining | https://conductscience.org/library/genes/3669 | NCBI Gene |
| KRT20 | 54474 | PubTator's text mining | https://conductscience.org/library/genes/54474 | NCBI Gene |
| NCAM1 | 4684 | PubTator's text mining | https://conductscience.org/library/genes/4684 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22856463
GET https://conductscience.org/api/papers/v1/22856463/references?page=2